🔎 Trials Near Me

Home › Multiple Myeloma

Multiple Myeloma clinical trials recruiting in the U.S.

239 studies for Multiple Myeloma are recruiting participants at sites across the United States.

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.

Cities with the most studies

By state

Recently updated studies

18F-Fluciclovine PET/CT in Multiple Myeloma

RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Nov 12, 2026 · NCT06103838

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Nov 12, 2026 · NCT02682667

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

RecruitingPhase 3
Ages 18 to 79 · All sexes · Updated Nov 12, 2026 · NCT07285239

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT06993675

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05969860

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Nov 4, 2026 · NCT05366881

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Nov 4, 2026 · NCT07221032

BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07009899

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07393282

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05201781

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Nov 3, 2026 · NCT07149857

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT04634552

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

RecruitingObservational study
Ages 10 and older · All sexes · Updated Nov 3, 2026 · NCT06323447

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07099391

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07341867

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.